Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Test Your Knowledge Previous | All Articles This Week | Next
This article originally posted 08 June, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 629

Special Feature -- GLP-1 Test Your Knowledge #629: Mary Ann is a 53 year-old white female 5'6" and 197 lbs who has been diagnosed with...

Mary Ann is a 53 year-old white female 5'6" and 197 lbs who has been diagnosed with type 2 diabetes for the past 9 years.

Advertisement

Due to changes in health insurance plans she is on her 4th prescriber since diagnosis and has been through a variety of diabetes medication combinations. Her A1c is currently at 7.8 and she is currently taking metformin 2000mg/day and Glipizide 10 mg bid which she started about 6 months ago. She had discontinued taking glucose levels due to the pain associated with testing.

Her new physician had her start testing one meal each day before and 2 hours after each meal and found that her glucose would increase an average of 65-70 mg/dl after each ppg reading. During the time she had been on the Glipizide she had gained 9 lbs and was seemingly hungry all the time.

She also takes, lisinopril 5mg qd, naproxen 500 bid, and Nexium 20mg qd

She was referred to a diabetes education class and had learned about carb counting and claimed that she had lowered her carbohydrates to under 160gm/ day.

On this office visit her glucose was 184 mg/dl after her meal and the prescriber decided to add a new medication.

Based on the information given the best choice would be

1.    GLP-1 agonist

2.    Basal Insulin

3.    DPP4-I

4.    Bile Acid Sequestrant 

For the correct answer, please click here.  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 June, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 629

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

2013 Most Popular Articles:

Mortality Risk in Patients with Type 2 Diabetes
Posted May 23, 2013
Bacteria in the Gut Improves the Management of Obesity and Type 2 Diabetes
Posted May 23, 2013
Hypoglycemia Treatment and Prevention Related to Physical Activity
Posted May 31, 2013
Scientist Use Bone Marrow Stem Cells to Cure Type 1 Diabetes
Posted June 06, 2013
Simvastatin Can Reduce the Benefits of Exercise in Active Adults
Posted May 23, 2013
Diabetes Epidemic Growing
Posted May 23, 2013
Co-Q10 May Offset Risk of Diabetes with Statin Use
Posted May 23, 2013
Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response
Posted June 06, 2013
FDA Advisory Panel Votes to Remove Avandia's Highly Restrictive Label
Posted June 06, 2013
Frequency of Blood Glucose Testing in Type 1's: How Often is Enough?
Posted June 13, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control
Search Articles On Diabetes In Control